Three generations of GLP-1 class drugs, three different receptor profiles, and vastly different efficacy. Mechanism, weight loss data, cardiovascular outcomes, side effects, and who each drug is actually right for.
Five years ago, this comparison didn't exist. The GLP-1 drug class consisted of semaglutide and liraglutide, one was clearly superior, and the clinical question was whether GLP-1 agonists were really worth the cost and injection burden. Then tirzepatide arrived in 2022 with a dual GLP-1/GIP mechanism and weight loss results that exceeded everything before it. Then Phase 2 data for retatrutide dropped in 2023 with a triple GLP-1/GIP/glucagon mechanism and weight loss numbers that exceeded tirzepatide.
In two years, the ceiling of what a single drug can do for metabolic health moved from 15% to 24%. That is a remarkable and fast-moving clinical landscape.
The fundamental difference between these three drugs is their receptor specificity. Understanding this determines everything else — efficacy, mechanism, side effects, and which patients benefit most.
| Drug | GLP-1 | GIP | Glucagon | Status |
|---|---|---|---|---|
| Semaglutide (Ozempic/Wegovy) | Yes | No | No | FDA Approved |
| Tirzepatide (Mounjaro/Zepbound) | Yes | Yes | No | FDA Approved |
| Retatrutide (LY3437943) | Yes | Yes | Yes | Phase 3 / Under FDA Review |
Each added receptor delivers additional metabolic benefit:
No head-to-head trial between all three drugs exists yet. The comparison must be assembled from separate trials with different populations and doses. But the efficacy gradient is clear and consistent:
Semaglutide 2.4 mg/week (Wegovy):
Tirzepatide 15 mg/week (Zepbound):
Retatrutide 12 mg/week (LY3437943):
The efficacy step-up is clear: approximately 15% to 22% to 24%+ with each generation. In absolute terms, for a 100 kg individual, this is the difference between losing 15 kg, 22 kg, and 24+ kg.
The side effect profile is remarkably similar across all three drugs — predominantly GI symptoms reflecting their shared GLP-1 mechanism — with some important differences.
Shared side effects across all three:
Differences from semaglutide to tirzepatide: Tirzepatide generally shows better GI tolerability at equivalent weight loss efficacy — the GIP component appears to modulate nausea through central GIP receptor effects.
New considerations with retatrutide (glucagon receptor):
Semaglutide: SELECT trial (NEJM 2023) — 20% reduction in MACE vs placebo in adults with obesity and established cardiovascular disease over 3.3 years. This is the foundational cardiovascular outcomes dataset in the class.
Tirzepatide: The SURPASS-CVOT trial in type 2 diabetes showed cardiovascular non-inferiority. A dedicated cardiovascular outcomes trial for obesity (SURMOUNT-MMO) is expected to report in 2026. The expectation is that cardiovascular outcomes will match or exceed semaglutide given its superior metabolic efficacy.
Retatrutide: TRIUMPH-3, the cardiovascular outcomes trial, is still enrolling and will not read out before the initial approval decision. We do not yet have MACE data for retatrutide. The reasonable expectation — based on greater weight loss, comparable GLP-1/GIP mechanisms, and the SELECT trial precedent — is that cardiovascular benefit will equal or exceed semaglutide. But this is extrapolation, not evidence yet.
Semaglutide is right for:
Tirzepatide is right for:
Retatrutide is right for (once approved):
Every efficacy comparison misses the most important longevity variable: lean mass preservation. GLP-1 class drugs produce weight loss from both fat and muscle. On semaglutide, approximately 40% of weight lost is lean mass without resistance training — a serious concern for longevity, since muscle mass independently predicts healthspan and lifespan.
The prescription for any GLP-1 class drug from a longevity standpoint is non-negotiable: ≥1.6 g/kg/day of dietary protein, plus 3–4 sessions per week of compound resistance training. This converts GLP-1 weight loss from partially counterproductive (losing muscle) to clearly beneficial (losing fat while preserving or building muscle).
See our 2026 retatrutide FDA status update for the latest Phase 3 timeline, and our alternatives guide for how to access the best available option right now.
Is retatrutide stronger than tirzepatide?
In Phase 2 trials, yes — 24.2% weight loss with retatrutide vs 22.5% with tirzepatide in their respective (separate) trials. A direct head-to-head trial is expected but not yet reported. The efficacy advantage is real but the magnitude may be smaller than headline numbers suggest in direct comparison.
Which drug has the best safety profile?
Semaglutide has the longest safety track record and most post-market exposure. Tirzepatide's profile is well-characterized after its 2022 approval. Retatrutide's profile is still being established in Phase 3 — the glucagon-related heart rate increase requires ongoing monitoring.
Can I switch from semaglutide to tirzepatide to retatrutide sequentially?
Sequential use is clinically rational when the response to the current drug is insufficient. Many physicians already manage patients through semaglutide to tirzepatide progressions. Retatrutide will add a third step on the efficacy ladder once approved.
As an Amazon Associate, Stacking Years earns from qualifying purchases.
Continuous wear
Over-the-counter continuous glucose monitor — real-time data on how food, exercise, stress, and sleep affect your blood sugar. The fastest way to personalize your metabolic health strategy.
Rating: 4.5/5
View on Amazon · Affiliate link
One-time read
Practical strategies for flattening blood glucose spikes through meal sequencing, food choices, and timing — directly applicable to metabolic health and longevity.
Rating: 4.6/5
View on Amazon · Affiliate link
One-time read
The definitive longevity medicine guide — covering exercise, nutrition, sleep, and emotional health as pillars of a longer, healthier life. Required reading for anyone serious about healthspan.
Rating: 4.8/5
View on Amazon · Affiliate link